Submitted by Anonymous (not verified) on 9 November 2023 - 11:59
Human medicines European public assessment report (EPAR): Oyavas, bevacizumab, Colorectal Neoplasms;Breast Neoplasms;Ovarian Neoplasms;Fallopian Tube Neoplasms;Peritoneal Neoplasms;Carcinoma, Non-Small-Cell Lung;Carcinoma, Renal Cell;Uterine Cervical Neoplasms, Date of authorisation: 26/03/2021, Revision: 6, Status: Authorised
Source: